Journal
CURRENT PHARMACEUTICAL ANALYSIS
Volume 10, Issue 3, Pages 161-168Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1573412910666140619210406
Keywords
Accuracy profiles; mu SPE; tyrosine kinase inhibitors; UPLC; UV-VIS detection; validation
Categories
Funding
- FRMH (Fond pour la Recherche medicale en Hainaut)
- FNRS (Fond National de la Recherche Scientifique)
Ask authors/readers for more resources
Tyrosine kinase inhibitors (TKIs) are a class of targeted drugs with antiangiogenic and antitumor activities. Due to inter-individual metabolic variability, an accurate therapeutic drug monitoring (TDM) represents a key element for the patient treatment. Here a fast and easily accessible method for the quantification of 3 TKIs (with one active metabolite) in human plasma after extraction is described. Sample pre-treatments were performed by solid phase extraction (Oasis (R) MCX mu Elution technology). Chromatographic separation was performed on a Waters Acquity UPLC (R) system with diode array detection (DAD) using a gradient of ammonium formate-acetonitrile on BEH C18 2.1x50 mm column. The analytical methods were validated by using the accuracy profiles approach (beta-expectation set at 95%). The methods were successfully validated for sunitinib (10 - 250 ng/mL), N-desethyl sunitinib (15 - 250 ng/mL), axitinib (15 - 250 ng/mL) and pazopanib (20 - 200 mu g/mL). The first concentration levels validated were considered as limit of quantification (LOQ). The validated method will be used in a clinical research study to determine TKI plasma levels and in this way help physicians to optimize the posology in order to achieve the best therapeutic response for their patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available